Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 6

Role of tipranavir in treatment of patients with multidrug-resistant HIV

Authors Joshua D Courter, Colleen J Teevan, Michael H Li, et al

Published Date September 2010 Volume 2010:6 Pages 431—441

DOI http://dx.doi.org/10.2147/TCRM.S4207

Published 23 September 2010

Joshua D Courter1,2, Colleen J Teevan1, Michael H Li1, Jennifer E Girotto1,2, Juan C Salazar1,2,3
1University of Connecticut School of Pharmacy, Storrs, 2Connecticut Children’s Medical Center, Hartford, 3University of Connecticut School of Medicine, Hartford, Connecticut, USA

Abstract: The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.

Keywords: tipranavir, HIV, multidrug resistance

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read: